We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Read MoreHide Full Article
Key Takeaways
KROS plans a phase II DMD study start in Q2 2026, a key execution milestone for rinvatercept.
KROS will engage regulators in 2H 2026 on ALS study design, expanding pipeline potential.
Takeda's elritercept progress, including a phase III study, supports milestones and royalties for KROS.
Keros Therapeutics (KROS - Free Report) enters 2026 with a tighter focus on rinvatercept and a reshaped cost profile after moving elritercept development spending to Takeda. The next 12 months are set up as an execution story, with timelines and partner activity likely to drive sentiment more than quarterly income statement optics. Three milestones stand out as potential “reset” points for how investors frame the opportunity.
KROS Catalyst 1: The Q2 2026 DMD Study Start
The planned phase II initiation of rinvatercept in Duchenne muscular dystrophy in the second quarter of 2026 is a clear proof-of-execution checkpoint. This is the moment when planning turns into patient enrollment, site activation, and real-world operational cadence.
What investors will likely watch most closely is timeline discipline. Any slippage risks pushing the next catalyst window out and weighing on confidence, especially with the program’s importance to the broader narrative. A clean start on schedule would help validate management’s ability to advance a wholly owned lead asset through pivotal development steps.
Keros Catalyst 2: 2H 2026 ALS Regulatory Talks
Keros also plans to engage regulatory authorities in the second half of 2026 to discuss the design of a phase II study evaluating rinvatercept in amyotrophic lateral sclerosis. That kind of formal interaction can expand the program narrative beyond a single indication and broaden how investors think about the pipeline’s opportunity set.
The key is that regulatory engagement can make the ALS plan feel more “real” and more investable. It frames the next phase as a defined development pathway rather than a concept, and it can sharpen investor expectations around what endpoints, patient populations, and study structure could look like once phase II planning is finalized.
KROS Catalyst 3: Elritercept Progress Under Takeda
Even though elritercept is now partner-led outside mainland China, Hong Kong, and Macau, progress can still matter to KROS because the collaboration preserves upside through milestone payments and tiered royalties. The deal includes potential additional development, commercial, and sales milestones totaling up to $1.1 billion, plus tiered royalties in the low double-digits to high teens on net sales, subject to customary reductions.
The most tangible recent datapoint is Takeda’s phase III RENEW study in myelodysplastic syndromes, which dosed its first patient in July 2025. That event triggered a $10 million milestone payment to Keros under the global licensing agreement. Continued partner execution can keep optionality alive while Keros concentrates internal resources on rinvatercept.
A central risk is that reported revenue can swing sharply because it is driven by partner economics rather than product sales. In 2025, total revenues surged to $244.1 million, largely from license revenue recognized under the Takeda agreement and transition services support.
That backdrop can normalize quickly. In the fourth quarter, revenue was just $0.4 million and consisted only of service and other revenue tied to transition services, with no license revenue recognized in the period. This pattern can keep quarterly results volatile and limit how much confidence investors place in near-term headline numbers.
KROS Balance Sheet vs. Spending Creep
Keros ended 2025 with $287.4 million in cash and cash equivalents and expects that balance to fund operations into the first half of 2028, based on current operating assumptions. The longer runway helps reduce financing overhang heading into key rinvatercept milestones.
The watch item is spending creep. There is no quantified 2026 expense outlook, and expanding clinical activity can pull forward external costs. Even with a leaner research and development base after transferring elritercept responsibilities to Takeda, investors are likely to track whether operating expenses rise as multiple programs move into more active clinical stages.
Keros Bottom Line: What Would Change the 2026 Narrative
The 2026 setup comes down to three pillars: rinvatercept execution, partner-driven de-risking, and cleaner financial visibility. A timely DMD phase II start in the second quarter of 2026 is the most direct proof point. Regulatory engagement on ALS in the second half of 2026 can widen the storyline and reinforce the breadth of the neuromuscular plan. Progress in Takeda’s phase III RENEW study, after first patient dosing in July 2025, can still influence Keros through milestones and royalty economics.
Competition also shapes sentiment in DMD. Sarepta Therapeutics (SRPT - Free Report) has an established franchise and received approval actions for Elevidys across ambulatory and non-ambulatory patients, while PTC Therapeutics (PTCT - Free Report) markets Emflaza. Against that backdrop, hitting the next rinvatercept deadlines and improving revenue repeatability are the factors most likely to reset how the market frames KROS in 2026.
View the Zacks #1 Rank List
Image: Bigstock
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Key Takeaways
Keros Therapeutics (KROS - Free Report) enters 2026 with a tighter focus on rinvatercept and a reshaped cost profile after moving elritercept development spending to Takeda. The next 12 months are set up as an execution story, with timelines and partner activity likely to drive sentiment more than quarterly income statement optics. Three milestones stand out as potential “reset” points for how investors frame the opportunity.
KROS Catalyst 1: The Q2 2026 DMD Study Start
The planned phase II initiation of rinvatercept in Duchenne muscular dystrophy in the second quarter of 2026 is a clear proof-of-execution checkpoint. This is the moment when planning turns into patient enrollment, site activation, and real-world operational cadence.
What investors will likely watch most closely is timeline discipline. Any slippage risks pushing the next catalyst window out and weighing on confidence, especially with the program’s importance to the broader narrative. A clean start on schedule would help validate management’s ability to advance a wholly owned lead asset through pivotal development steps.
Keros Catalyst 2: 2H 2026 ALS Regulatory Talks
Keros also plans to engage regulatory authorities in the second half of 2026 to discuss the design of a phase II study evaluating rinvatercept in amyotrophic lateral sclerosis. That kind of formal interaction can expand the program narrative beyond a single indication and broaden how investors think about the pipeline’s opportunity set.
The key is that regulatory engagement can make the ALS plan feel more “real” and more investable. It frames the next phase as a defined development pathway rather than a concept, and it can sharpen investor expectations around what endpoints, patient populations, and study structure could look like once phase II planning is finalized.
KROS Catalyst 3: Elritercept Progress Under Takeda
Even though elritercept is now partner-led outside mainland China, Hong Kong, and Macau, progress can still matter to KROS because the collaboration preserves upside through milestone payments and tiered royalties. The deal includes potential additional development, commercial, and sales milestones totaling up to $1.1 billion, plus tiered royalties in the low double-digits to high teens on net sales, subject to customary reductions.
The most tangible recent datapoint is Takeda’s phase III RENEW study in myelodysplastic syndromes, which dosed its first patient in July 2025. That event triggered a $10 million milestone payment to Keros under the global licensing agreement. Continued partner execution can keep optionality alive while Keros concentrates internal resources on rinvatercept.
Keros Therapeutics, Inc. Price and Consensus
Keros Therapeutics, Inc. price-consensus-chart | Keros Therapeutics, Inc. Quote
Keros Monitor: Non-Recurring Revenue Normalization
A central risk is that reported revenue can swing sharply because it is driven by partner economics rather than product sales. In 2025, total revenues surged to $244.1 million, largely from license revenue recognized under the Takeda agreement and transition services support.
That backdrop can normalize quickly. In the fourth quarter, revenue was just $0.4 million and consisted only of service and other revenue tied to transition services, with no license revenue recognized in the period. This pattern can keep quarterly results volatile and limit how much confidence investors place in near-term headline numbers.
KROS Balance Sheet vs. Spending Creep
Keros ended 2025 with $287.4 million in cash and cash equivalents and expects that balance to fund operations into the first half of 2028, based on current operating assumptions. The longer runway helps reduce financing overhang heading into key rinvatercept milestones.
The watch item is spending creep. There is no quantified 2026 expense outlook, and expanding clinical activity can pull forward external costs. Even with a leaner research and development base after transferring elritercept responsibilities to Takeda, investors are likely to track whether operating expenses rise as multiple programs move into more active clinical stages.
Keros Bottom Line: What Would Change the 2026 Narrative
The 2026 setup comes down to three pillars: rinvatercept execution, partner-driven de-risking, and cleaner financial visibility. A timely DMD phase II start in the second quarter of 2026 is the most direct proof point. Regulatory engagement on ALS in the second half of 2026 can widen the storyline and reinforce the breadth of the neuromuscular plan. Progress in Takeda’s phase III RENEW study, after first patient dosing in July 2025, can still influence Keros through milestones and royalty economics.
Competition also shapes sentiment in DMD. Sarepta Therapeutics (SRPT - Free Report) has an established franchise and received approval actions for Elevidys across ambulatory and non-ambulatory patients, while PTC Therapeutics (PTCT - Free Report) markets Emflaza. Against that backdrop, hitting the next rinvatercept deadlines and improving revenue repeatability are the factors most likely to reset how the market frames KROS in 2026.
KROS Zacks Rank
Keros currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.